Skip to main content

In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG.

Publication ,  Journal Article
Carnicelli, AP; Granger, CB
Published in: Ann Intern Med
January 21, 2020

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

January 21, 2020

Volume

172

Issue

2

Start / End Page

JC3

Location

United States

Related Subject Headings

  • Humans
  • General & Internal Medicine
  • Dyslipidemias
  • Coronary Artery Bypass
  • Cardiovascular Diseases
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Carnicelli, A. P., & Granger, C. B. (2020). In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG. Ann Intern Med, 172(2), JC3. https://doi.org/10.7326/ACPJ202001210-003
Carnicelli, Anthony P., and Christopher B. Granger. “In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG.Ann Intern Med 172, no. 2 (January 21, 2020): JC3. https://doi.org/10.7326/ACPJ202001210-003.
Carnicelli, Anthony P., and Christopher B. Granger. “In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG.Ann Intern Med, vol. 172, no. 2, Jan. 2020, p. JC3. Pubmed, doi:10.7326/ACPJ202001210-003.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

January 21, 2020

Volume

172

Issue

2

Start / End Page

JC3

Location

United States

Related Subject Headings

  • Humans
  • General & Internal Medicine
  • Dyslipidemias
  • Coronary Artery Bypass
  • Cardiovascular Diseases
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences